Clarification Regarding Diamyd’s NP2 project
The Company would like to clarify that at this time there are no formal partnership negotiations ongoing regarding NP2, as suggested in media. A structured out-licensing process for NP2 is intended to be initiated after results from a planned Phase II study in cancer patients are available. Diamyd announced earlier today that to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center,